CF Bankshares Inc.: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 13, 2023 and accepted by EDGAR at Nov 13, 2023, 14:41 ET.
Management's discussion and analysis
As filed, 1,440 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
(a) None.
(b) Not applicable.
(c) The following table provides information concerning purchases of the Holding Company’s shares of common stock made by or on behalf of the Company or any “affiliated purchaser” as defined in Rule 10b-18(a)(3) under the Securities Exchange Act of 1934, as amended, during the three months ended September 30, 2023.
| Period | Total number of common shares purchased | Average price paid per common share | Total number of common shares purchased as part of publicly announced plans or programs (3) | Maximum number of common shares that may yet be purchased under the plans or programs | |
|---|---|---|---|---|---|
| July 1, 2023 through July 31, 2023 | 1,428 | (1) | 16.64 | - | 250,000 |
| August 1, 2023 through August 31, 2023 | - | - | - | 250,000 | |
| September 1, 2023 through September 30, 2023 | 1,053 | (2) | 18.01 | - | 250,000 |
| Total | 2,481 | $17.22 | - | 250,000 |
(1) Represents shares of common stock surrendered to the Company for the payment of taxes upon the vesting of restricted stock.
(2) Represents shares of common stock surrendered to the Company for the payment of the exercise price and taxes upon the exercise of stock options.
(3) On July 5, 2023, the Company’s Board of Directors authorized a new stock repurchase program pursuant to which the Company may repurchase up to 250,000 shares of the Company’s common stock on or before June 30, 2024.
Risk factors
As filed, 450 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There are certain risks and uncertainties in our business that could cause our actual results to differ materially from those anticipated. A detailed discussion of our risk factors is included in “Item 1A. Risk Factors” of Part I of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as supplemented by “Item IA. Risk Factors” of Part II of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Interest expense | 3 months2023-07-01 to 2023-09-30 | $16.5m | us-gaap:InterestExpense |
| Interest expense | 9 months2023-01-01 to 2023-09-30 | $42.7m | us-gaap:InterestExpense |
| Income tax | 3 months2023-07-01 to 2023-09-30 | $984.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-01-01 to 2023-09-30 | $3.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-07-01 to 2023-09-30 | $4.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-01-01 to 2023-09-30 | $12.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-07-01 to 2023-09-30 | $0.62 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-01-01 to 2023-09-30 | $1.97 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-07-01 to 2023-09-30 | $0.63 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-01-01 to 2023-09-30 | $1.98 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-07-01 to 2023-09-30 | 6,456,575 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-01-01 to 2023-09-30 | 6,439,931 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-01-01 to 2023-09-30 | $10.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-01-01 to 2023-09-30 | $648.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2023-01-01 to 2023-09-30 | $1.1m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2023-09-30 | $229.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Total assets | At period end2023-09-30 | $1.99bn | us-gaap:Assets |
| Total liabilities | At period end2023-09-30 | $1.84bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-09-30 | $151.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001070680-23-000039. Last ingested by Listed: Nov 13, 2026, 01:50 ET. Listed shows no prices and gives no investment advice.